SCHEMBL1702652

SCHEMBL1702652

CC(C)(C)c1cc(-c2ccc(NS(C)(=O)=O)cc2)c2ncc(-c3ccc(NS(C)(=O)=O)cc3)nc2c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 2/20 0.47
KDM4E B2RXH2 1/20 0.47
ALDH1A1 P00352 1/20 0.47
LMNA P02545 1/20 0.47
HSP90AA1 P07900 1/20 0.47
MAPT P10636 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
NPC1 O15118 1/20 0.45
JAK2 O60674 1/20 0.45
RAB9A P51151 1/20 0.45
ATR Q13535 1/20 0.41
SGK1 O00141 6/20 0.40
MAPK10 P53779 2/20 0.40
IDO1 P14902 1/20 0.40
TDO2 P48775 1/20 0.40
NR3C2 P08235 1/20 0.39
KIF11 P52732 1/20 0.39
IKBKB O14920 1/20 0.39
CHUK O15111 1/20 0.39
TP53 P04637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1702674 0.85 CYP3A4 (0.45) HPGDKDM4EALDH1A1LMNAHSP90AA1
SCHEMBL1703193 0.84 SGK1 (0.40) HPGDKDM4EALDH1A1LMNAHSP90AA1
SCHEMBL3765201 0.73 ALOX5AP (0.45) NPC1JAK2RAB9AKITCYP3A4
SCHEMBL1703319 0.73 MET (0.40) NPC1JAK2RAB9ACYP3A4
SCHEMBL16643950 0.72 HPGD (0.50) HPGDKDM4EALDH1A1LMNAHSP90AA1
SCHEMBL3771679 0.71 KIT (0.40) KIT
SCHEMBL1702649 0.71 MET (0.35) NPC1JAK2RAB9ASGK1MEN1
SCHEMBL15306550 0.71 ATR (0.57) HPGDNPC1JAK2RAB9AATR
SCHEMBL1702697 0.71 CYP3A4 (0.38) HSP90AA1NPC1JAK2RAB9ASGK1
SCHEMBL16508267 0.69 NPC1 (0.41) HPGDKDM4EALDH1A1LMNAHSP90AA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2440528-B1 HETEROCYCLIC ANTIVIRAL COMPOUNDS HOFFMANN LA ROCHE (CH) 2014-10-08 EP claimed
EP-2440528-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS F. Hoffmann-La Roche AG (CH) 2012-04-18 EP claimed
WO-2010142656-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2010-12-16 WO claimed
US-20100311760-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS DE VICENTE FIDALGO JAVIER 2010-12-09 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100311760-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS EIF2AK2, XDH, GTF3C4 HPGD 1585/4885KDM4E 1276/4885ALDH1A1 1266/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.